To analyze surgical success comparing a single medication (antifibrotic drug) with double medication (same antifibrotic plus antiproliferative drug) in trabeculectomy (filtrating surgery to decrease intraocular pressure in glaucoma patients)

ISRCTN ISRCTN93098069
DOI https://doi.org/10.1186/ISRCTN93098069
Secondary identifying numbers 20031992
Submission date
07/04/2020
Registration date
15/04/2020
Last edited
05/05/2021
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Surgery
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Background and study aims
Glaucoma is a common eye condition where the optic nerve, which connects the eye to the brain, becomes damaged. It's usually caused by fluid building up in the front part of the eye, which increases pressure inside the eye.
Trabeculectomy is a surgical operation which lowers the intraocular pressure inside the eye (IOP) in patients with glaucoma. This is achieved by making a small hole in the eye wall (sclera).
Avoiding excessive wound healing response remains a problem, once surgery success depends on maintaining patency of the fistula and bleb filtration. Antiproliferative agents such as mitomycin C (MMC) reduce inflammation and scarring process, improving surgical outcome. However, besides the high risk of potentially complications, studies have not proven to be fully satisfactory and new therapeutic approaches more effective and safer are currently been used to augment surgery. The use of antiangiogenic factors (such as bevacizumab) has been associated with slowing this proliferative and fibrotic process after filtration surgery.
The study aims to explore this promising modality to understand if bevacizumab is an important additional agent in improving the prognosis of glaucoma filtrating surgery.

Who can participate?, What does the study involve?
Data is extracted from medical charts of patients submitted to primary trabeculectomy for open-angle glaucoma at Centro Hospitalar Universitário Lisboa Norte and Hospital dos Lusíadas between October 2015 and March 2019

What are the possible benefits and risks of participating?
None (retrospective study)

Where is the study run from?
1. Centro Hospitalar Universitário Lisboa Norte (Portugal)
2. Hospital dos Lusíadas (Portugal)

When is the study starting and how long is it expected to run for?
September 2019 to May 2020

Who is funding the study?
Centro de Estudos das Ciências da Visão - Faculdade de Medicina da Universidade de Lisboa

Who is the main contact?
Dr Patrícia José, patricialopes1@campus.ul.pt

Contact information

Dr Patrícia José
Public

Centro Hospitalar Universitário Lisboa Norte
Av. Prof. Egas Moniz
Lisbon
1649-035
Portugal

ORCiD logoORCID ID 0000-0002-4523-7306
Phone +351 964958859
Email patricialopes1@campus.ul.pt

Study information

Study designObservational cross-sectional cohort study
Primary study designObservational
Secondary study designCross sectional study
Study setting(s)Hospital
Study typeTreatment
Participant information sheet Not available in web format, please use the contact details below to request a patient information sheet.
Scientific titleTrabeculectomy with mitomycin C or with mitomycin C plus intracameral bevacizumab injection? A comparative study
Study objectivesTo analyze the benefits of using intracameral bevacizumab injection as an add on to the standard of care use of mitomycin C (MMC) in trabeculectomy.
Ethics approval(s)Approved 17/12/2019, Ethics Committee of Centro Hospitalar Universitário Lisboa Norte and Hospital dos Lusíadas (R. Abílio Mendes, 1500-458, Lisbon, Portugal; +351 966 184 461; knowledgecenter@lusiadas.pt), ref: n/a
Health condition(s) or problem(s) studiedTrabeculectomy
InterventionData is extracted from medical charts (background history, glaucoma characteristics, baseline IOP, preoperative visual acuity, number of ocular hypotensive medication, safety parameters, follow-up from visits on day 1; at weeks 1, 4; at months 3, 6, 12 and 24 after trabeculectomy, number of postoperative IOP-lowering medication and surgical interventions). All consecutive patients from one site (Centro Hospitalar Universitário Lisboa Norte) received standard of care; all consecutive patients from the second site (Hospital dos Lusíadas) received the becavizumab as an add on to standard of care. Statistical analysis is carried out using SPSS software (Chicago, IL, version 24.0).
Intervention typeProcedure/Surgery
Primary outcome measureThe absolute and qualified surgical success rate of trabeculectomy at 12 months and 24 months defined as intraocular pressure ≤18 mmHg and >5mmHg with at least 30% reduction in IOP from baseline
Secondary outcome measures1. Intra- and postoperative complications measured using patient records
2. Additional effects of bevacizumab measured using patient records
Overall study start date01/09/2019
Completion date01/05/2020

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
SexBoth
Target number of participantsReview of entire set of patients within the time range (128 patients assessed for study)
Total final enrolment128
Key inclusion criteria1. Patients submitted to primary trabeculectomy for open-angle glaucoma between October 2015 and March 2019
2. No other previous surgeries, except uncomplicated phaco
3. ≥ 18 years and have agreed to chart review as per GDPR regulations
Key exclusion criteria1. Pregnancy or breastfeeding
2. Combination with cataract surgery
3. History of another eye disease
4. Uncontrolled blood pressure (systolic >180 mmHg and/or diastolic >100 mmHg while a patient is at rest)
5. Severe cardiovascular disease (including a stroke or a myocardial infarction 6 months before)
6. Known allergic reaction to bevacizumab or MMC
Date of first enrolment01/10/2015
Date of final enrolment01/03/2019

Locations

Countries of recruitment

  • Portugal

Study participating centres

Centro Hospitalar Universitário Lisboa Norte
Av. Prof. Egas Moniz
Lisbon
1649-028
Portugal
Hospital dos Lusíadas
R. Abílio Mendes 12
Lisbon
1500-258
Portugal

Sponsor information

Centro Hospitalar Lisboa Norte
Hospital/treatment centre

Hospital Lusíadas
Av. Prof Egas Moniz
Lisbon
1649-028
Portugal

Phone +351 962958859
Email patricialopes1@campus.ul.pt
Website http://www.chln.min-saude.pt/
ROR logo "ROR" https://ror.org/020sr6z07

Funders

Funder type

University/education

Universidade de Lisboa
Government organisation / Universities (academic only)
Alternative name(s)
Universitas Olisiponensis, University of Lisbon, Technical University of Lisbon, ULisboa | Universidade de Lisboa, University of Lisbon, Portugal, New University of Lisbon (Portugal), ULisboa
Location
Portugal

Results and Publications

Intention to publish date31/12/2020
Individual participant data (IPD) Intention to shareYes
IPD sharing plan summaryOther
Publication and dissemination planThe results of this study should be published in a high-visibility peer-reviewed journal.
IPD sharing planAll data generated or analysed during this study will be included in the subsequent results publication.

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article 30/04/2021 05/05/2021 Yes No

Editorial Notes

05/05/2021: Publication reference added.
09/04/2020: Trial’s existence confirmed by Hospital dos Lusíadas